- Food & Drug Administration grants Sernova Corp. notice of approval to utilize its Continuous Glucose Monitoring System in support of clinical trial of its Cell Pouch
- Global treatment market for type 1 diabetes on pace to grow to $13.6 billion by 2023
- Sernova is a clinical stage company focusing on treatment of type 1 diabetes, hemophilia and other chronic metabolic diseases
Sernova Corp. (OTCQB: SEOVF) (TSX.V: SVA) (FSE: PSH) has been approved to add its Continuous Glucose Monitoring System in support of the impending clinical trial of its Cell Pouch™ for the treatment of type 1 diabetes. The system will enable the tracking of transplanted cells and measurement of key efficacy at multiple times following the transplant of therapeutic cells into the Cell Pouch (http://nnw.fm/TyyZ8).
Sernova, based in London, Ontario, is a clinical stage company that develops disruptive regenerative medical technologies for the treatment of chronic diseases, such as diabetes and hemophilia. It is focused on treating type 1 diabetes and other chronic metabolic diseases requiring replacement of proteins or hormones that are…
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com